每经AI快讯，9月12日，药捷安康-B(02617.HK)午后涨近88%，高见204.6港元，较招股价13.15港元已涨 超1455%。截至发稿，涨53.08%，报166.4港元，成交额10.33亿港元。 ...

Core Viewpoint - The stock of药捷安康-B (02617) has surged nearly 88%, reaching a high of 204.6 HKD, which is an increase of over 1455% from its IPO price of 13.15 HKD, driven by positive developments in its clinical trials and inclusion in the Hong Kong Stock Connect program [1] Group 1: Stock Performance - The stock price increased by 53.08% to 166.4 HKD with a trading volume of 10.33 billion HKD [1] - The stock has seen a significant rise since its IPO, reflecting strong market interest and investor confidence [1] Group 2: Company Developments - The company has been included in the Hong Kong Stock Connect program effective from September 8 [1] - The core product,替恩戈替尼, is the first and only FGFR inhibitor to enter the registration clinical stage for treating recurrent or refractory cholangiocarcinoma [1] - The drug has shown clinical efficacy evidence for treating metastatic castration-resistant prostate cancer [1] Group 3: Clinical Trial Updates - The company received clinical implied approval from the National Medical Products Administration of China for a Phase II trial of替恩戈替尼 combined with fulvestrant for HR+ and HER2- recurrent or metastatic breast cancer on September 10 [1] - A Phase II open-label, multicenter clinical study of替恩戈替尼 in combination with other treatments for advanced hepatocellular carcinoma has recently completed its first patient dosing [1] - The drug has been granted Fast Track designation by the FDA for the treatment of metastatic castration-resistant prostate cancer [1]

Group 1 - The Hang Seng Index rose by 1.53%, gaining 398 points to reach 26,484 points, while the Hang Seng Tech Index increased by 2.18% with a morning trading volume of 184.9 billion HKD [1] - Zai Lab's stock surged over 55%, with a three-month increase exceeding 800%, and its market capitalization surpassed 66 billion HKD following the approval of a Phase II trial for its drug [1] - Cloud computing stocks continued to rise, driven by Oracle's substantial computing orders and North American cloud providers increasing capital expenditure budgets, with GDS Holdings up 16% and Alibaba rising by 5.93% [1] Group 2 - Domestic property stocks saw gains as first-tier cities introduced new real estate policies, which are expected to stimulate market demand, with China Overseas Land up 16% and Country Garden rising by 9.68% [1] - China Hongqiao's stock increased by over 6% due to strong expectations of interest rate cuts benefiting aluminum prices, with the company's equity capacity expected to enhance profits [1] - Tianyue Advanced's stock rose over 10%, with institutions optimistic about the potential applications of silicon carbide materials in high-end computing chips [1] Group 3 - Bilibili's stock increased by 3% as the testing date for its new game was set for October, with institutions optimistic about the company's growth potential supported by AI [1] - China Shipbuilding Defense's stock rose over 5% amid ongoing supply-demand tensions in the shipbuilding industry, with attention on the group's progress in addressing competition [1] Group 4 - Juxing Legend's stock surged over 15% as it prepares to unveil its "Juxing Dog" in collaboration with Yushu Technology this weekend [2] - Nocoda Technology's stock soared over 39% after signing a cooperation agreement with Alpha AI for low-altitude economic intelligent drones [3] - Ark Health's stock rose over 13% following a strategic partnership with Innovent Biologics to develop services in the "AI + weight loss" sector [3]

Group 1 - Evergrande Property (06666) resumed trading and rose over 28% as Evergrande and liquidators plan to sell shares, with potential transactions in preliminary stages [1] - Alibaba-W (09988) increased by over 5% and Baidu Group-W (09888) rose over 8% as both companies began using internally designed chips to train their AI models, replacing some NVIDIA chips [1] - China Merchants Energy (01138) saw a rise of over 5% after announcing plans to issue A-shares to raise no more than 8 billion yuan for fleet upgrades, with increased oil production expected to boost shipping demand [1] - Kangfang Biologics (09926) increased by over 4% after presenting excellent clinical data for its drug at WCLC, highlighting its global market value [1] - NIO-SW (09866) rose over 3% as it plans to publicly issue $1 billion in shares, with Goldman Sachs expecting the funds to support the company's product strategy [1] - WanGuo Data-SW (09698) surged over 15% as AI drives data center demand, with the company fully engaging in partnerships with cloud service providers [1] - Jiajian Ankang-B (02617) rose over 32%, with its market capitalization exceeding 50 billion HKD after receiving approval for a Phase II trial of its drug [1] Group 2 - Meitu (01357) increased by over 6% after announcing a partnership with Alibaba's Tongyi Laboratory to enhance its products with advanced AI models [2] - Robotics concept stocks mostly rose, with UBTECH (09880) up over 3%, ShouCheng Holdings (00697) up over 3%, Yuejiang (02432) up over 4%, and Jizhi Jia-W (02590) up over 6%, as domestic and international catalysts for humanoid robot commercialization are expected [2] - Bilibili-W (09626) rose over 2% as it revealed its new strategy card game "Three Kingdoms: Hundred Generals Card," with institutions optimistic about the company's growth potential with AI integration [2] Group 3 - Alibaba (BABA.US) rose 8.00% after the launch of the "Gaode Street Ranking," which attracted over 40 million users on its first day, becoming the largest food ranking in China [3] - XPeng Motors (XPEV.US) increased by 2.39% after receiving a special flight permit for its "land aircraft" (X3-F) in the UAE [3] - Trip.com (TCOM.US) rose 3.21% after forming a five-year strategic partnership with Cityline, marking its first collaboration with a major ticket supplier in Hong Kong and Macau [3] - NIO (NIO.US) increased by 6.21% after completing a $1 billion equity issuance, marking its second public financing plan this year [3] - Kingsoft Cloud (KC.US) rose 5.60% as Citigroup raised its target price to $20, citing strong AI-related demand from Xiaomi [3] - NetEase (NTES.US) continued to rise by 2.98%, reaching a historical high after launching its first sci-fi shooting mobile game based on the "Destiny" IP [3] Group 4 - Adobe (ADBE.US) rose 0.11% after launching its first AI agent product suite to help customers streamline workflows across various applications [4] - Hesai (HSAI.US) increased by 0.90% as sources reported its Hong Kong IPO priced at HKD 212.8 per share, raising at least HKD 3.62 billion with oversubscription nearly 120 times [4] - Tesla (TSLA.US) rose 6.04% as the Model Y L is set to launch in the domestic market on September 19, with orders extending to November [4] - Online real estate platform Opendoor (OPEN.US) surged 79.52% after appointing Kaz Nejatian as the new CEO, with co-founder Keith Rabois returning to the board [4]

药捷安康称，替恩戈替尼靶向FGFR/VEGFR、JAK、Aurora，目前没有其他MTK抑制剂具有相同的靶向 组合。因此，在一些疾病治疗上，替恩戈替尼已经展现出独特价值。另外，该款产品正在逐步打通全球 化路径，已获国家药品监督管理局（NMPA）授予治疗胆管癌的突破性治疗品种认定及美国食品药品监 督管理局（FDA）授予治疗胆管癌及转移性去势抵抗性前列腺癌的快速通道认定，亦获FDA授予用于治 疗胆管癌的孤儿药认定，以及欧洲药品管理局（EMA）授予用于治疗胆道癌的孤儿药认定。 消息面上，药捷安康近日公布，公司核心产品替恩戈替尼（Tinengotinib，TT-00420）联合氟维司群治 疗经治失败的激素受体阳性（HR+）且人表皮生长因子受体2阴性或低表达（HER2-）的复发或转移性 乳腺癌II期临床试验，已于2025年9月10日获得了中国国家药品监督管理局的临床默示许可。 智通财经APP获悉，药捷安康-B(02617)再涨超18%，高见129.3港元再创新高，总市值一度突破500亿港 元。截至发稿，涨15%，报125港元，成交额1.51亿港元。 ...

Core Viewpoint - The stock of药捷安康-B (02617) has surged over 18%, reaching a new high of 129.3 HKD, with a market capitalization exceeding 50 billion HKD, driven by positive clinical trial news for its core product, Tinengotinib [1] Company Developments -药捷安康 announced that its core product, Tinengotinib (TT-00420), in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration (NMPA) in China for a Phase II trial targeting hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer, with the trial set to commence on September 10, 2025 [1] - The company highlighted that Tinengotinib targets FGFR/VEGFR, JAK, and Aurora, and currently, no other MTK inhibitors possess the same targeted combination, showcasing its unique value in treating certain diseases [1] Regulatory Approvals - Tinengotinib has been recognized as a breakthrough therapy for cholangiocarcinoma by the NMPA and has received fast track designation from the FDA for both cholangiocarcinoma and metastatic castration-resistant prostate cancer [1] - Additionally, the FDA has granted orphan drug designation for cholangiocarcinoma and the European Medicines Agency (EMA) has also awarded orphan drug status for cholangiocarcinoma treatment [1]

每经AI快讯，药捷安康-B(02617.HK)再涨超15%，总市值一度突破400亿港元。截至发稿，涨11.11%， 报100港元，成交额1.48亿港元。 ...

智通财经APP获悉，药捷安康-B(02617)再涨超15%，总市值一度突破400亿港元。截至发稿，涨 11.11%，报100港元，成交额1.48亿港元。 此外，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生效。国元国际表 示，公司在细分行业研发领先，替恩戈替尼是全球首个且唯一进入注册临床阶段用于治疗复发或难治性 胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前 列腺癌具有临床疗效证据的研究药物。 消息面上，药捷安康公布，核心产品替恩戈替尼(TT-00420)联合氟维司群治疗经治失败的激素受体阳性 (HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已获中国国 家药品监督管理局的临床默示许可。替恩戈替尼联合氟维司群的临床治疗策略可能为乳腺癌患者的治疗 带来新的突破。 ...

药捷安康-B(02617)再涨超15%，总市值一度突破400亿港元。截至发稿，涨11.11%，报100港元，成交 额1.48亿港元。 消息面上，药捷安康公布，核心产品替恩戈替尼(TT-00420)联合氟维司群治疗经治失败的激素受体阳性 (HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已获中国国 家药品监督管理局的临床默示许可。替恩戈替尼联合氟维司群的临床治疗策略可能为乳腺癌患者的治疗 带来新的突破。 此外，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生效。国元国际表 示，公司在细分行业研发领先，替恩戈替尼是全球首个且唯一进入注册临床阶段用于治疗复发或难治性 胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前 列腺癌具有临床疗效证据的研究药物。 ...

Major Events - The clinical trial for the combination treatment of Tienogtinin and Furvestrant for HR-positive/HER2-negative or low-expressing recurrent or metastatic breast cancer has been approved for Phase II [1] - Feiyang Group's subsidiary signed a strategic cooperation framework agreement with Qingdao Cultural Property Exchange Center for potential collaboration in the digitalization of cultural tourism assets [1] - Kaizhile International entered the TCG sector by reaching an operational service cooperation with the globally renowned IP Pokémon [1] - CIMC Group's BWO plans to lease two lifting living platforms, "Huaye Long" and "Huashang Long," to Hailong 16 and Hailong 17 companies [1] - Goldwind Technology intends to invest 18.92 billion in building a wind-hydrogen-ammonia integrated project in Inner Mongolia [1] Financial Data - Zhongyuan Jianye reported a contract sales of 7.28 billion for the first eight months, a year-on-year decrease of 20.0% [1] - Jianye Real Estate's total property contract sales for the first eight months reached 5.62 billion, down 5.0% year-on-year [1] - Baoshen International's cumulative operating income net for the first eight months was approximately 11.555 billion, a decline of 8.1% year-on-year [1] - China Resources Power's subsidiary power plants sold a total of 144 million megawatt-hours in the first eight months, an increase of 5.9% year-on-year [1] - Jiangshan Holdings reported a total solar power generation of approximately 218.2 thousand megawatt-hours in the first eight months, a decrease of 3.55% year-on-year [1]